| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Geraniol — an acyclic monoterpene alcohol and fragrance compound found in citronella, palmarosa, rose, lemongrass, rose-geranium, and several other essential oils. It is formally classified as a plant-derived monoterpenoid natural product; Citronella oil is not equivalent to geraniol: it is a variable multi-component essential oil distilled primarily from Cymbopogon winterianus or Cymbopogon nardus, with citronellal, geraniol, citronellol, geranyl acetate, limonene, and other terpenes as principal constituents. Primary mechanisms (ranked):
Bioavailability / PK relevance: Geraniol is lipophilic and can be absorbed after oral administration, but it is rapidly distributed and extensively converted to geranic acid, dihydrogeranic acid, glucuronide conjugates, and other metabolites. Rat studies indicate a short blood half-life and large formulation-dependent differences in oral bioavailability. Recent mouse studies likewise show rapid metabolism, so free-geraniol exposure is transient. Emulsions, lipid carriers, nanoformulations, and encapsulation may increase exposure, but these delivery systems do not establish clinical anticancer efficacy. Citronella-oil composition and exposure vary substantially with species, chemotype, cultivation, storage, and formulation. In-vitro vs systemic exposure relevance: Many anticancer experiments use geraniol concentrations in the tens to hundreds of micromolar range, and some use still higher levels. These sustained concentrations may exceed free systemic concentrations achievable through ordinary dietary or flavouring exposure because geraniol is rapidly metabolized and cleared. Direct comparison is difficult because human plasma PK data for therapeutic dosing are limited. Cytotoxic findings from undiluted or concentrated citronella oil should not be attributed solely to geraniol because citronellal, citronellol, methyl isoeugenol, limonene, and minor constituents may contribute independently or interact. Clinical evidence status: Preclinical. Evidence consists primarily of cancer-cell studies, chemically induced animal-tumour models, and xenograft studies. Geraniol has shown enhancement of 5-fluorouracil in colorectal-cancer models, but there are no established randomized controlled trials demonstrating that isolated oral or systemic geraniol treats cancer. A clinical study of a multi-ingredient topical essential-oil formulation for HPV-related disease cannot establish geraniol-specific efficacy. Neither geraniol nor citronella oil is an approved anticancer treatment or validated oncology adjunct. Safety / regulatory relevance: Geraniol is widely used as a flavouring and fragrance ingredient, while citronella oil is also used as a flavouring and insect-repellent ingredient. Food-use safety evaluations do not establish safety at pharmacological anticancer doses. Geraniol is a recognized fragrance allergen and can cause allergic contact dermatitis, particularly after oxidation. Concentrated citronella oil can irritate skin, eyes, mucosa, and the gastrointestinal tract and should not be treated as interchangeable with food-grade geraniol. Citronella oil also contains composition-dependent constituents, including methyl isoeugenol in some preparations, that require separate toxicological consideration. Geraniol Cancer Mechanisms
|
| Source: |
| Type: |
| MAPK3 (ERK1) ERK proteins are kinases that activate other proteins by adding a phosphate group. An overactivation of these proteins causes the cell cycle to stop. The extracellular signal-regulated kinase (ERK) signaling pathway is a crucial component of the mitogen-activated protein kinase (MAPK) signaling cascade, which plays a significant role in regulating various cellular processes, including proliferation, differentiation, and survival. high levels of phosphorylated ERK (p-ERK) in tumor samples may indicate active ERK signaling and could correlate with aggressive tumor behavior EEk singaling is frequently activated and is often associated with aggressive tumor behavior, treatment resistance, and poor outcomes. |
| 6568- | Ger, | Perturbation by geraniol of cell membrane permeability and signal transduction pathways in human colon cancer cells |
| - | in-vitro, | Colon, | Caco-2 |
| 6570- | Ger, | Apoptosis-Mediated Anticancer Activity of Geraniol Inhibits NF-κB, MAPK, and JAK-STAT-3 Signaling Pathways in Human Thyroid Cancer Cells |
| - | in-vitro, | Thyroid, | TPC-1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:414 Target#:105 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid